The rate of immunohistochemical staining with gelsolin was found to be significantly higher in tumor tissues of patients with an advanced clinical stage than in patients with an early clinical stage (positive gelsolin expression was 79.8% for advanced-stage LSCC and 54.6% for early-stage LSCC, p < 0.05). The gene discussed is GSN; the disease is neoplasm.